Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.

Phase 1

Not yet recruiting

Conditions: Healthy Subjects

Interventions: Drug: MT-7117
Drug: Placebo

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 40

Registration Number: NCT06994286

Locations: 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China

Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers

Phase 1

Active, not recruiting

Conditions: Healthy Adult Male Volunteers

Interventions: Biological: Placebo
Biological: MT-3534

First Posted Date: 2024-07-01

Last Posted Date: 2025-05-20

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 56

Registration Number: NCT06482346

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan

An Exploratory Study of MT-2990 in Patients With AAV

Phase 1

Recruiting

Conditions: Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Interventions: Drug: MT-2990

First Posted Date: 2024-01-09

Last Posted Date: 2025-01-16

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 10

Registration Number: NCT06196905

Locations: 🇯🇵
Hiroshima University Hospital, Hiroshima-shi, Hiroshima, Japan
🇯🇵
Kagawa University Hospital, Kita-gun, Kagawa, Japan
🇯🇵
Saitama Medical University Hospital, Iruma-gun, Saitama, Japan

and more 5 locations

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: MT-2111

First Posted Date: 2022-12-20

Last Posted Date: 2025-06-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 49

Registration Number: NCT05658562

Locations: 🇯🇵
Fukushima Medical University Hospital, Fukushima-shi, Fukushima, Japan
🇯🇵
Gifu Municipal Hospital, Gifu-shi, Gifu, Japan
🇯🇵
Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan

and more 20 locations

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

Phase 3

Completed

Conditions: ALS

Interventions: Drug: MT-1186

First Posted Date: 2022-10-05

Last Posted Date: 2025-02-03

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 15

Registration Number: NCT05568615

Locations: 🇯🇵
National Hospital Organization Higashinagoya National Hospital, Nagoya-shi, Aichi, Japan
🇯🇵
National Hospital Organization Chibahigashi National Hospital, Chiba-shi, Chiba, Japan
🇯🇵
Fukushima Medical University Hospital, Fukushima-shi, Fukushima, Japan

and more 8 locations

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

Phase 1

Completed

Conditions: Healthy Adult Males

Interventions: Biological: MT-3921
Biological: Placebo

First Posted Date: 2022-05-31

Last Posted Date: 2023-01-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 10

Registration Number: NCT05396235

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: MT-1186

First Posted Date: 2022-04-22

Last Posted Date: 2024-01-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 16

Registration Number: NCT05342597

Locations: 🇯🇵
Investigational site, Tokyo, Japan

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

Phase 1

Completed

Conditions: HTLV-1-Associated Myelopathy (HAM)

Interventions: Biological: MT-3921
Biological: Placebo

First Posted Date: 2022-02-15

Last Posted Date: 2024-01-29

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 15

Registration Number: NCT05240612

Locations: 🇯🇵
St. Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan

A Study of MT-0551 in Patients With Systemic Sclerosis

Phase 3

Active, not recruiting

Conditions: Systemic Sclerosis

Interventions: Drug: Inebilizumab
Drug: Placebo

First Posted Date: 2022-01-20

Last Posted Date: 2025-06-13

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 80

Registration Number: NCT05198557

Locations: 🇯🇵
University of Fukui Hospital, Yoshida-gun, Fukui, Japan
🇯🇵
Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
🇯🇵
St. Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan

and more 1 locations

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Painful Diabetic Peripheral Neuropathy

Interventions: Drug: MT-8554
Drug: Placebo

First Posted Date: 2021-11-17

Last Posted Date: 2022-11-22

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 156

Registration Number: NCT05123196

Locations: 🇯🇵
Yachiyo Hospital, Anjo-City, Aichi, Japan
🇯🇵
Japan Organization of Occupational Health and Safety Chubu Rosai Hospital, Nagoya-City, Aichi, Japan
🇯🇵
JUNEIKAI Medical Corporation Akaicho Clinic, Chiba-shi, Chiba, Japan

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy